153 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
2 Jun 14
Other Events
12:00am
Committee recommends continuation of study after safety review of 80 standard risk hepatoblastoma patients
Research Triangle Park, NC — June 2, 2014 –Adherex … 6
Edward A. Neuwelt, M.D., Professor at Oregon Health & Science University presented the ongoing safety results from SIOPEL 6 on behalf of the SIOPEL
10-K/A
2009 FY
FENC
Fennec Pharmaceuticals Inc
7 Feb 11
Annual report (amended)
12:00am
the combination of cisplatin plus STS, as well as the safety, tolerability and anti-tumor activity in both arms of the study. Under the terms of our agreement … , SIOPEL will conduct and fund the clinical activity and we will provide drug, drug distribution and pharmacovigilance, or safety monitoring
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
6 Jun 23
Other Events
5:39pm
for Human Use (CHMP) earlier this year. The CHMP’s decision was based on safety and efficacy data from two pivotal open-label, randomized Phase 3 trials … for intravenous use in pediatric patients.7 PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing
8-K
EX-99.1
f6exntzj
17 Oct 22
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States
9:13am
8-K
EX-99.1
kqbj8kxdndz3tth
4 Apr 23
Other Events
12:32pm
8-K
EX-99.1
vvum601um
21 Sep 22
Other Events
3:49pm
8-K
EX-99.1
eowigrd5
26 Sep 22
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment
5:03pm
8-K
EX-99.1
lnlo0s
7 Jan 13
Adherex Announces Completion of Patient Enrollment and Maintains TSX Listing Status
12:00am
8-K
EX-99.1
hwjv4wmdi o5r8l5
10 Dec 12
Adherex Reports Positive Preliminary Interim Phase II Results
12:00am
8-K
EX-99.1
h53up jlcnb5
11 Aug 20
Other Events
10:18am